[go: up one dir, main page]

WO2001081919A3 - Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose - Google Patents

Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose Download PDF

Info

Publication number
WO2001081919A3
WO2001081919A3 PCT/US2001/013378 US0113378W WO0181919A3 WO 2001081919 A3 WO2001081919 A3 WO 2001081919A3 US 0113378 W US0113378 W US 0113378W WO 0181919 A3 WO0181919 A3 WO 0181919A3
Authority
WO
WIPO (PCT)
Prior art keywords
impaired
diabetes
type
diagnostic test
gastric inhibitory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/013378
Other languages
French (fr)
Other versions
WO2001081919A2 (en
Inventor
Michael A Nauck
Juris J Meier
Katrin Huecking
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNebraska Inc
Original Assignee
BioNebraska Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNebraska Inc filed Critical BioNebraska Inc
Priority to EP01930773A priority Critical patent/EP1356295A2/en
Priority to CA002405900A priority patent/CA2405900A1/en
Priority to AU2001257278A priority patent/AU2001257278A1/en
Priority to KR1020027014447A priority patent/KR20020097236A/en
Publication of WO2001081919A2 publication Critical patent/WO2001081919A2/en
Anticipated expiration legal-status Critical
Publication of WO2001081919A3 publication Critical patent/WO2001081919A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Methods and kits for determining whether an individual is susceptible to developing impaired glucose tolerance (IGT), impaired fasting glucose (IFG), or Type-2 diabetes are described. Such methods include administering GIP or GIP variant and nutrient to an individual, measuring the response of the individual and determining whether the individual is susceptible to developing IGT, Type-2 diabetes, or IFG.
PCT/US2001/013378 2000-04-27 2001-04-26 Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose Ceased WO2001081919A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01930773A EP1356295A2 (en) 2000-04-27 2001-04-26 Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucos
CA002405900A CA2405900A1 (en) 2000-04-27 2001-04-26 Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
AU2001257278A AU2001257278A1 (en) 2000-04-27 2001-04-26 Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
KR1020027014447A KR20020097236A (en) 2000-04-27 2001-04-26 Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55977900A 2000-04-27 2000-04-27
US09/559,779 2000-04-27

Publications (2)

Publication Number Publication Date
WO2001081919A2 WO2001081919A2 (en) 2001-11-01
WO2001081919A3 true WO2001081919A3 (en) 2003-04-24

Family

ID=24234987

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/013378 Ceased WO2001081919A2 (en) 2000-04-27 2001-04-26 Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose

Country Status (5)

Country Link
EP (1) EP1356295A2 (en)
KR (1) KR20020097236A (en)
AU (1) AU2001257278A1 (en)
CA (1) CA2405900A1 (en)
WO (1) WO2001081919A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2008530130A (en) * 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド GIP analogs and hybrid polypeptides with selectable properties
CA2628241C (en) 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP2059818A2 (en) * 2006-05-15 2009-05-20 Digilab, Inc. Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes
EP1857818A1 (en) * 2006-05-15 2007-11-21 DIGILAB BioVisioN GmbH Diagnostic and therapeutic uses of peptides for pre-forms of type 2 diabetes and conditions associated therewith
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
CA2674354A1 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
GEP20135944B (en) 2007-02-15 2013-10-25 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
ES2558155T3 (en) 2007-10-30 2016-02-02 Indiana University Research And Technology Corporation Compounds showing glucacon antagonist activity and GLP-1 agonist
CN102105159B (en) 2008-06-17 2015-07-08 印第安纳大学研究及科技有限公司 GIP-based mixed agonists for the treatment of metabolic disorders and obesity
EP2307037A4 (en) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUES HAVING PHYSIOLOGICAL PH BUFFERS HAVING ENHANCED SOLUBILITY AND STABILITY
TWI474832B (en) 2008-06-17 2015-03-01 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
PE20120332A1 (en) 2008-12-19 2012-04-14 Univ Indiana Res & Tech Corp PEPTIDE PROPHARS FROM THE GLUCAGON SUPERFAMILY BASED ON AMIDA
RU2012101274A (en) 2009-06-16 2013-07-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon Compounds Active Against the GIP Receptor
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX2012008603A (en) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
JP6121323B2 (en) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Peptides of the glucagon superfamily exhibiting nuclear hormone receptor activity
JP6050746B2 (en) 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Glucagon superfamily of peptides exhibiting G protein-coupled receptor activity
MX2012014576A (en) 2010-06-24 2013-02-21 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs.
CN103458920B (en) 2010-12-22 2016-07-06 印第安那大学科技研究公司 Show the glucagon analogs of GIP receptor active
KR20140043793A (en) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
SI2723367T1 (en) 2011-06-22 2017-08-31 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
MX2014003579A (en) 2011-11-17 2015-04-10 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting glucocorticoid receptor activity.
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
CN108627651A (en) * 2013-09-20 2018-10-09 阿斯图特医药公司 The method and composition of the differentiation of diagnosis and prognosis and the abdominal pain cause of disease for appendicitis
US10317359B2 (en) 2016-01-05 2019-06-11 Ravi Kumar Meruva Differential carbon dioxide sensor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0479210A2 (en) * 1990-10-05 1992-04-08 Sanwa Kagaku Kenkyusho Co., Ltd. GIP analogues and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0479210A2 (en) * 1990-10-05 1992-04-08 Sanwa Kagaku Kenkyusho Co., Ltd. GIP analogues and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
B. NYHOLM, M. WALKER, C.H. GRAVHLOT, P.A. SHEARING, J. STURIS, K.G.M.M. ALBERTI, J.J. HOLST, O. SCHMITZ: "Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrate and gut incretin hormones in healthy offsspring of type II(non-insulin-dependent) dibetic parents: evidence of several aberrations", DIABETOLOGIA, vol. 42, 1999, pages 1314 - 1323, XP002208949 *
J.J. HOLST, J. GROMADA, M.A. NAUCK: "The pathogenesis of NIDDM involves a defective expression of the GIP receptor", DIABETOLOGIA, vol. 40, 1997, pages 984 - 986, XP002208950 *
M.A. NAUCK, M.M. HEIMESAAT, C. ORSKOV, J.J. HOLST, R. EBERT, W. CREUTZFELDT: "Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus", J. CLIN.INVEST., vol. 91, no. 1, 1993, pages 301 - 307, XP001095159 *
N.N. RUDOWITSCH, D.DICK, M.A. NAUCK, H. SCHATZ, A.F.H. PFEIFFER: "Modified hyperglycemic clamp to detect phenotypic marker of genetic defects leading to type 2 dibetes", DIABETOLOGIA, vol. 43, no. sup.1, August 2000 (2000-08-01), pages A142, XP001095169 *

Also Published As

Publication number Publication date
WO2001081919A2 (en) 2001-11-01
EP1356295A2 (en) 2003-10-29
KR20020097236A (en) 2002-12-31
CA2405900A1 (en) 2001-11-01
AU2001257278A1 (en) 2001-11-07

Similar Documents

Publication Publication Date Title
WO2001081919A3 (en) Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
IL151570A0 (en) Method for diagnosing immunologic food sensitivity
EP1318399A3 (en) Passive sample detection to initiate timing of an assay
TW200502550A (en) Colorimetric sensors constructed of diacetylene materials
HK1052218A1 (en) Compositions containing a urea derivative dye for detecting an analyte
CA2331812A1 (en) 13c glucose breath test for the diagnosis of diabetic indications and monitoring glycemic control
NO982156L (en) Diagnostic test device
ATE321340T1 (en) ULTRA-SENSITIVE MONITORING OF SENSORS AND PROCESSES
CA2448713A1 (en) Analytical instruments, biosensors and methods thereof
WO2000058514A3 (en) Methods for improving sensitivity and specificity of screening assays
NO932363L (en) DIAGNOSTIC METHOD FOR DETECTING RETURN OF FOETAL MEMBRANES AND TEST KITS USING THIS
NO995690L (en) Compounds for the diagnosis of tuberculosis and methods for their use
NO973381D0 (en) Diagnostic test device with test layers consisting of several layers, and method for determining an analyte by means of this
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
EE05675B1 (en) Method for diagnosis or detection of conformational disease, required test procedure, reagent kit and device
CA2112702A1 (en) Assay methods and compositions for detecting serum proteases, particularly activated protein c
CA2130947A1 (en) Dry Elements, Test Devices, Test Kits and Methods for Chemiluminescent Detection of Analytes Using Peroxidase-Labeled Reagents
WO2004015420A8 (en) Method for diagnosing multiple sclerosis
NO177463C (en) STLV-III Related Polypeptides, Diagnostic Test Kits, and In Vitro Assay Procedure for Detecting Anti-HIV-2 Antibodies in Body Fluid Test
ATE147410T1 (en) IGM ANTIBODIES AGAINST PROTAMIN
MX9709360A (en) Method for the detection of compounds that modulate the effects of the obese protein.
DE50007635D1 (en) METHOD FOR DIAGNOSIS OF SJÖGREN SYNDROME
DE68912151D1 (en) Electrochemical sensors for immunological test procedures.
CA2213083A1 (en) Detection of antibody production
CA2346406A1 (en) Detection of pleiotrophin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CO CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 578954

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2001257278

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2405900

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020027014447

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001930773

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018117716

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020027014447

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001930773

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001930773

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020027014447

Country of ref document: KR